clinical trial · NCT06500884
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Janssen Research & Development, LLC·phase2·recruiting·n = 210
Multiple MyelomaTalquetamabProphylaxis AProphylaxis BProphylaxis CProphylaxis DRamantamig
brief summary
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.
started
Aug 26, 2024
primary completion
May 30, 2030
completion
May 30, 2030
last updated
Sep 25, 2026
official title
A Phase 2, Open-label, Randomized Study to Evaluate GPRC5D-related Oral Events
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol